Rilutek: What it is, How it Works, and How it Benefits Patients with ALS
Rilutek is the first effective treatment for people with ALS. Although researchers
don’t fully understand how Rilutek works, one explanation is that Rilutek may protect
nerve cells from overexposure to a substance called glutamate.
This protection could explain the effect of Rilutek on the survival of people with
ALS. Glutamate is a substance the body naturally makes that carries signals to the
motor neurons. This is one link in the chain of how the brain tells the muscles
what to do. Too much glutamate may cause dysfunction and death of motor neurons
so that they can’t carry the brain’s messages to the muscles, resulting in weakness.
Over 1,100 patients have participated in clinical trials for Rilutek. During the
first year of treatment, patients who took Rilutek had a better chance of survival
compared to patients who took a placebo (sugar pill).
However, by the end of 18 months, there was no difference between the Rilutek group
and those on placebo. Rilutek is not a cure for ALS, and it cannot give back physical
function that is already lost.